Shenyang Xingqi Pharmaceutical Co Ltd (300573) — Net Asset Quality Index
Shenyang Xingqi Pharmaceutical Co Ltd (300573) has a Net Asset Quality Index of 76.8% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.42 Billion minus total liabilities of CN¥562.18 Million yields net assets of CN¥1.86 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read how much debt does Shenyang Xingqi Pharmaceutical Co Ltd carry for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shenyang Xingqi Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2011–2024)
This chart shows how Shenyang Xingqi Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the index stands at 76.8%, representing net assets of CN¥1.86 Billion against total assets of CN¥2.42 Billion CNY. For live market cap and overall valuation, see 300573 market cap overview.
Annual Net Asset Quality Index for Shenyang Xingqi Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Net Asset Quality Index for Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check 300573 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 74.9% | CN¥1.59 Billion | CN¥2.13 Billion | CN¥534.48 Million | ▼ -8.6 pp |
| 2023 | 83.5% | CN¥1.69 Billion | CN¥2.02 Billion | CN¥333.92 Million | ▼ -3.6 pp |
| 2022 | 87.1% | CN¥1.55 Billion | CN¥1.78 Billion | CN¥230.63 Million | ▲ +7.4 pp |
| 2021 | 79.7% | CN¥1.34 Billion | CN¥1.69 Billion | CN¥342.35 Million | ▲ +7.8 pp |
| 2020 | 71.9% | CN¥694.06 Million | CN¥965.70 Million | CN¥271.64 Million | ▲ +4.4 pp |
| 2019 | 67.4% | CN¥574.90 Million | CN¥852.37 Million | CN¥277.46 Million | ▼ -10.8 pp |
| 2018 | 78.3% | CN¥554.58 Million | CN¥708.47 Million | CN¥153.89 Million | ▼ -3.5 pp |
| 2017 | 81.8% | CN¥553.38 Million | CN¥676.48 Million | CN¥123.09 Million | ▲ +9.6 pp |
| 2016 | 72.2% | CN¥520.95 Million | CN¥721.41 Million | CN¥200.47 Million | ▲ +12.3 pp |
| 2015 | 59.9% | CN¥389.79 Million | CN¥650.94 Million | CN¥261.15 Million | ▲ +5.1 pp |
| 2014 | 54.8% | CN¥367.81 Million | CN¥670.90 Million | CN¥303.09 Million | ▼ -4.6 pp |
| 2013 | 59.4% | CN¥336.80 Million | CN¥567.21 Million | CN¥230.41 Million | ▼ -10.2 pp |
| 2012 | 69.5% | CN¥290.70 Million | CN¥418.02 Million | CN¥127.32 Million | ▼ -22.7 pp |
| 2011 | 92.2% | CN¥247.00 Million | CN¥267.88 Million | CN¥20.88 Million | — |